[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Cancer Trials Ireland\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":192},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,46,71,94,117,141,164],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100635398","phase-2-inspire-innovative-sabr-for-prostate-cancer-all-ireland-100635398",false,"NCT07552168","INSPIRE: INnovative SABR for Prostate Cancer All IREland","Inclusion Criteria:\n\n1. Written informed consent obtained prior to any study-related procedures\n2. Males ≥ 18 years of age\n3. ECOG performance status (PS) 0-2\n4. Biopsy-proven prostate adenocarcinoma without neuro-endocrine differentiation (within 18 months prior to registration, unless on active surveillance and re-biopsy not clinically indicated)\n5. Gleason score ≤ 4+3\n6. Clinical and\u002For MRI stage T1c-T3a, N0-X, M0-X\n7. PSA ≤ 30 ng\u002Fml (within 60 days prior to registration \u002F prior to starting androgen-deprivation therapy (ADT\u002Fhormone therapy) \\[PSA ≤ 15 ng\u002Fml for patients on 5-alpha reductase inhibitors\\]\n8. Patients belonging to one of the following risk groups:\n\n   * Low risk - patients meeting all of the following criteria:\n\n     * Gleason ≤ 6\n     * Clinical stage T1c-T2a\n     * PSA \\\u003C 10 ng\u002Fml (within 60 days prior to registration)\n   * Intermediate risk - patients meeting any of the following criteria, assuming no high-risk features apply:\n\n     * Gleason 7 (3+4 or 4+3)\n     * MRI stage T2b-T2c (N0, M0-X)\n     * PSA 10-20 ng\u002Fml (within 60 days prior to registration)\n   * High risk - patients with tumours that meet a maximum of one of the following criteria:\n\n     * MRI stage T3a (N0, M0)\n     * PSA \\>20 - ≤30 ng\u002Fml (within 60 days prior to registration)\n\nExclusion Criteria:\n\n1. Previous malignancy within the last 2 years (except basal cell carcinoma (BCC) or squamous carcinoma of the skin), or if previous malignancy is expected to significantly compromise 5 year survival\n2. Prior pelvic radiotherapy\n3. Any prior active treatment for prostate cancer (with the exception of ADT). Patients previously on active surveillance are eligible if they continue to meet all other eligibility criteria.\n4. Life expectancy \\\u003C5 years.\n5. Bilateral hip prostheses or any other implants\u002Fhardware that would introduce substantial CT artefacts\n6. Medical conditions likely to make radiotherapy inadvisable e.g. inflammatory bowel disease, significant urinary symptoms.\n7. Anticoagulation with warfarin\u002Fbleeding tendency making fiducial placement or surgery unsafe in the opinion of the clinician. Note: Anti-platelet agents e.g. aspirin, clopidogrel and DOACs such as apixaban, rivaroxaban are not contraindications to trial entry.\n8. Participation in another concurrent treatment protocol for prostate cancer (not including QoL, survivorship, exercise or registry studies).","MALE","18 Years",{"count":18,"type":19},136,"ESTIMATED","INTERVENTIONAL",[22],"PHASE2","This is a Phase II, single arm, multi-centre, prospective clinical trial evaluating next generation Stereotactic Ablative Radiotherapy (SABR) for low, intermediate, and eligible high-risk prostate cancer. Eligible patients will receive next generation prostate SABR incorporating toxicity reduction strategies",[25],"Prostate Adenocarcinoma",[27,28,29,30,31,32],"SABR","Prostate cancer","Prostate adenocarcinoma","Low-risk prostate cancer","Intermediate-risk prostate cancer","High-risk prostate cancer","RECRUITING","2026-05-28",{"date":36,"type":37},"2026-06-01","ACTUAL",{"date":39,"type":19},"2026-04",{"date":41,"type":19},"2034-11",{"name":43,"class":44},"Cancer Trials Ireland","NETWORK",3,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":53,"minAge":16,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":20,"phases":56,"briefSummary":58,"conditions":59,"keywords":61,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":45},"100625620","precision-oncology-clinical-diagnostic-study-in-primary-and-metastatic-breast-cancer-prism-100625620","NCT07425002","Precision Oncology Clinical Diagnostic Study In Primary and Metastatic Breast Cancer (PRISM)","PRISM","Inclusion Criteria:\n\n1. Patients diagnosed with primary breast cancer attending hospital for the resection of their tumour tissue. Or Patients with suspected or confirmed brain metastatic breast cancer (Patient has a history of a biopsy or surgically (i.e. pathologically) confirmed primary breast cancer) attending hospital for the resection\u002Fbiopsy and\u002For treatment of their tumour tissue. Or Patients with suspected (but not necessarily biopsy confirmed) newly diagnosed brain metastatic breast cancer attending hospital for the resection\u002Fbiopsy and\u002For treatment of their tumour tissue.\n2. Patients receiving neoadjuvant treatment are also eligible (if applicable).\n3. Patients must be ≥ 18 years of age.\n4. Patients must be able to give informed consent.\n\nExclusion Criteria:\n\n1. Patients who do not have a confirmed diagnosis of primary breast cancer.\n2. Patients whose participation, in the opinion of the PI, would not be in their best interest, or those whom in the opinion of the PI would be unsuitable for study for reasons of infirmity or poor health.","ALL",{"count":55,"type":19},1600,[57],"NA","This study aims to provide information about the genomics of your breast cancer which your oncologist can use to enhance the treatment of your disease possibly enabling more targeted and personalised therapy.This study will carry out TruSight Oncology Comprehensive (TSOComprehensive) testing on breast cancer tumour tissue that was collected at the time of your breast cancer diagnosis or during your breast surgery or if you have brain metastasis and you have had a biopsy for this. The TruSight Oncology Comprehensive assay is a next-generation sequencing (NGS) test used to analyse cancer-related genomic changes in patients, offering a comprehensive view of potential mutations and other alterations that can impact treatment decisions. The TruSight Oncology Comprehensive assay is CE-IVD marked for use in Europe, meaning that it complies with the relevant EU regulation, for comprehensive genomic profiling for different types of cancer. It analyses 523 cancer-relevant genes from both DNA and RNA to identify variations. It will also look for changes and mutations which may affect cell growth and stability. By identifying relevant mutations and biomarkers, the assay can help oncologists select the most appropriate treatment strategies with the aim of improving patient outcomes.",[60],"Breast Cancer",[62],"Breast cancer","2026-02-16",{"date":65,"type":37},"2026-02-20",{"date":67,"type":37},"2025-11-11",{"date":69,"type":19},"2030-12-30",{"name":43,"class":44},{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":75,"acronym":4,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":77,"minAge":16,"maxAge":4,"enrollmentInfo":78,"targetDuration":4,"studyType":80,"phases":4,"briefSummary":81,"conditions":82,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":93},"100196980","breast-cancer-proteomics-and-molecular-heterogeneity-100196980","NCT01840293","Breast Cancer Proteomics and Molecular Heterogeneity","Inclusion Criteria:\n\n1. Patients diagnosed with primary breast cancer attending hospital for the resection of their tumour tissue\n\n   Or\n\n   -Patients with suspected or confirmed recurrent or metastatic breast cancer (Patient has a history of a biopsy- or surgically- (i.e. pathologically) confirmed primary breast cancer) attending hospital for the resection\u002Fbiopsy and\u002For treatment of tumour tissue\n\n   Or\n\n   -Patient with suspected (but not necessarily biopsy confirmed) newly diagnosed stage 4 breast cancer attending hospital for the resection\u002Fbiopsy and\u002For treatment of their tumour tissue\n2. Patients receiving neoadjuvant treatment are also eligible (if applicable)\n3. Patients have to be ≥ 18 years of age\n4. Patients must be able to give informed consent","FEMALE",{"count":79,"type":19},1780,"OBSERVATIONAL","Primary objective:\n\nThe primary objective is to define the proteomic and molecular characteristics of primary and recurrent\u002F metastatic breast tumours with special focus on the expression of S100 protein and the estrogen receptor (ER), progesterone receptor (PR) and epidermal growth factor receptor 2 (HER2) genes\n\nSecondary objective:\n\n* To expand our understanding of the complex molecular pathways dictating the progression of breast cancer and their response to different treatment regimes.\n* To relate proteomic findings to survival data\n* To identify potential serum markers of breast cancer progression",[83,84],"Primary Breast Cancer","Recurrent\u002FMetastatic Breast Cancer","2025-12-15",{"date":87,"type":37},"2025-12-19",{"date":89,"type":37},"2013-02",{"date":91,"type":19},"2038-01",{"name":43,"class":44},6,{"id":95,"slug":96,"hasResults":11,"nctId":97,"briefTitle":98,"officialTitle":99,"acronym":4,"eligibilityCriteria":100,"healthyVolunteers":11,"sex":53,"minAge":16,"maxAge":4,"enrollmentInfo":101,"targetDuration":4,"studyType":20,"phases":103,"briefSummary":105,"conditions":106,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":116},"100517998","phase-1-dose-painted-intensity-modulated-radiotherapy-pancreas-dp-imrt-pancreas-100517998","NCT06024824","Dose-Painted Intensity Modulated Radiotherapy Pancreas (DP-IMRT Pancreas)","DP-IMRT Pancreas: A Non-randomised Phase I\u002FII Study of Dose-escalated Hypofractionated Dose-Painted Intensity Modulated Radiotherapy (DPIMRT) in Resectable\u002FBorderline Resectable Pancreatic Adenocarcinoma","Inclusion Criteria\n\n1. Written informed consent obtained prior to any study-related procedures\n2. Age ≥18 years\n3. ECOG (European Cooperative Oncology Group) performance status (PS) 0-2\n4. Resectable or borderline resectable per National Comprehensive Cancer Network (NCCN) criteria (see Appendix H)\n5. Patients with histologically confirmed Pancreatic Ductal Adenocarcinoma (PDAC), with the following staging: cT1N0-2, cT2N0-2, cT3N0-2 \\[American Joint Committee on Cancer (AJCC) 8th edition\\] (see Appendix C) who are planned for pre-operative systemic chemo-radiotherapy\n6. Imaging with Computed Tomography Thorax Abdomen and Pelvis (CT TAP) and Magnetic resonance imaging (MRI) Abdomen confirms no evidence of metastatic disease\n7. Females of child-bearing potential (see Appendix G) must not be pregnant (or lactating) and must be prepared to use adequate contraception methods during treatment. Males whose female partners are of child-bearing potential must be prepared to use adequate contraception methods during treatment.\n\nExclusion Criteria\n\n1. Previous thoracic or abdominal or pelvic radiation therapy (RT)\n2. Previous treatment for bilirubin regression, other than stenting\n3. Known co-existing or prior malignancy within the last 5 years (except for Basal Cell Carcinoma (BCC) or Squamous Cell Carcinoma (SCC) of the skin) which is likely to interfere with treatment or assessment of outcomes\n4. Syndromes or conditions associated with increased radiosensitivity\n5. Uncontrolled intercurrent illness that is likely to interfere with treatment or assessment of outcomes, or psychiatric illness\u002F social situations that would limit compliance with study requirements\n6. Evidence of any other significant clinical disorder or laboratory findings that makes it undesirable for the patient to participate in the study, or if it is felt by the research\u002F Medical team that the patient may not be able to comply with the protocol and follow up schedule due to psychological, familial, sociological or geographical conditions",{"count":102,"type":19},49,[104,22],"PHASE1","This is a prospective non-randomised Phase I\u002FII Radiotherapy (RT) study with patients recruited to escalated dose cohorts. Patients with resectable or borderline resectable (per the National Comprehensive Cancer Network (NCCN) criteria) pancreatic adenocarcinoma will receive dose-escalated hypofractionated DP-IMRT via Intensity Modulated Radiotherapy (IMRT) \u002F Volume Modulated Arc Therapy (VMAT).",[107],"Pancreatic Adenocarcinoma","2025-07-18",{"date":110,"type":37},"2025-07-20",{"date":112,"type":37},"2024-01-30",{"date":114,"type":19},"2031-07",{"name":43,"class":44},2,{"id":118,"slug":119,"hasResults":11,"nctId":120,"briefTitle":121,"officialTitle":121,"acronym":122,"eligibilityCriteria":123,"healthyVolunteers":11,"sex":53,"minAge":16,"maxAge":4,"enrollmentInfo":124,"targetDuration":4,"studyType":20,"phases":126,"briefSummary":127,"conditions":128,"keywords":130,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":132,"lastUpdatePostDateStruct":133,"startDateStruct":135,"completionDateStruct":137,"leadSponsor":139,"locationsCount":140},"100527575","exploring-the-impact-of-a-multi-modal-nutritional-intervention-in-patients-undergoing-chemotherapy-for-pancreatic-cancer-feed-trial-100527575","NCT06149546","Exploring the Impact of a Multi-modal Nutritional Intervention in Patients Undergoing Chemotherapy for Pancreatic Cancer (FEED Trial)","FEED","Inclusion Criteria:\n\n1. Ability to give signed informed consent and willing and able to comply with the protocol.\n2. Patients aged 18 years and above.\n3. Patients with newly diagnosed, pathologically confirmed pancreatic ductal adenocarcinoma who will undergo neoadjuvant chemotherapy following formal MDT assessment at St Vincent's University Hospital, specifically FOLFIRINOX or Gemcitabine with Nab-Paclitaxel (and\u002For any additional therapy regimen approved by NCCP).\n4. Patients have CT scan available and suitable for body composition analysis within 8 weeks prior to randomisation.\n5. Patients have adequate upper limb dexterity to allow assessment of hand grip strength.\n\nExclusion Criteria:\n\n1. Patients who are unable to consume oral diet and require prolonged enteral and\u002For parenteral nutritional support.\n2. Patient with any significant history of non-compliance to medical treatments or with inability to grant reliable informed consent.\n3. Patients who can\u002Fwill not consume fish and pork products due to allergy, intolerance, religious beliefs, or dietary preferences.\n4. Patients with known blood clotting disorders, e.g antiphospholipid syndrome, factor V Leiden syndrome, haemophilia \u002Fany liver disease which has progressed to liver cirrhosis where prolonged fish oil supplementation is unsafe.\n5. Patients with uncontrolled hypertension (BP \\>180\u002F110 mm Hg) which prohibits exercise.\n6. Patients with muscle wasting disorders, e.g. paraplegia, motor neuron disease, Duchenne muscular dystrophy, multiple sclerosis.\n7. Women who are pregnant or breastfeeding due to differing nutritional needs and macronutrient metabolism.",{"count":125,"type":19},70,[57],"The study will examine if a multi-modal nutritional care package, with or without resistance training delivered with neoadjuvant chemotherapy, is effective at preventing loss of muscle strength during neoadjuvant chemotherapy for pancreatic cancer. There are two arms in this study: Control Arm will receive standard dietetic care and be prescribed standard pancreatic enzyme replacement therapy and oral nutritional supplement drinks with their neoadjuvant chemotherapy. The intervention Arm will have 3 additional dietitian visits and 6 physiotherapist visits that the control group will not.",[129],"Pancreatic Cancer",[129,131],"Multi-modal Nutritional","2025-07-04",{"date":134,"type":37},"2025-07-08",{"date":136,"type":37},"2024-05-01",{"date":138,"type":19},"2028-11",{"name":43,"class":44},1,{"id":142,"slug":143,"hasResults":11,"nctId":144,"briefTitle":145,"officialTitle":145,"acronym":146,"eligibilityCriteria":147,"healthyVolunteers":11,"sex":53,"minAge":16,"maxAge":4,"enrollmentInfo":148,"targetDuration":4,"studyType":20,"phases":150,"briefSummary":151,"conditions":152,"keywords":154,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":156,"lastUpdatePostDateStruct":157,"startDateStruct":159,"completionDateStruct":161,"leadSponsor":163,"locationsCount":45},"100522145","phase-1-spine-sabr---dose-escalated-stereotactic-ablative-body-radiotherapy-sabr-for-solid-tumour-spine-metastases-100522145","NCT06078813","Spine SABR - Dose-escalated Stereotactic Ablative Body Radiotherapy (SABR) for Solid Tumour Spine Metastases","Spine-SABR","Inclusion Criteria:\n\n1. Written informed consent obtained prior to any study-related procedures\n2. ≥ 18 years of age\n3. Life expectancy \\> 6 months\n4. ECOG (Eastern Cooperative Oncology Group) performance status (PS) 0-2\n5. Histological diagnosis of malignant primary disease (excluding haematologic, seminomatous or small cell subtype)\n6. Diagnosis of oligometastatic disease (OMD) or oligoprogressive disease (OPD) defined as:\n\n   1. OMD where there are 1 to 5 metastatic lesions, with a controlled primary tumor being optional, but where all metastatic sites must be safely treatable (can be synchronous or metachronous to primary tumor diagnosis) with curative intent OR\n   2. OPD with 1 to 5 lesions progressing on a background of widespread but stable metastatic disease OR\n   3. Systemic therapy-induced OMD where there are 1 to 5 persistent lesions after systemic therapy, all safely treatable with SABR\n7. Single spinal level from C1 to L5 to be treated for the purpose of the study (co-existing lesion(s) on non-consecutive spinal level(s) may receive RT at Investigator discretion, if deemed unlikely to interfere with study treatment and assessment of outcomes).\n8. Stable spine assessed by Spinal Instability Neoplastic Score (SINS) (SINS 0-6, or SINS 7-12 and not for surgical intervention).\n9. Bilsky Grade 0-1a (i.e. minimal (epidural impingement, without deformation of thecal sac) or no epidural disease) as confirmed by Radiation Oncologist\n10. Able to lie flat in the treatment position for radiotherapy for up to 60 minutes\n11. Females of childbearing potential must not be pregnant or lactating, and must be prepared to take adequate contraception methods during treatment. Males whose female partners are of childbearing potential must be prepared to take adequate contraception methods during treatment. Examples of effective contraception methods are a condom or a diaphragm with spermicidal jelly, or oral, injectable or implanted birth control\n\nExclusion Criteria:\n\n1. Previous radiotherapy or surgery to the proposed SABR treatment site which is likely to interfere with treatment or assessment of outcomes (for radiotherapy, this includes prior thoracic radiotherapy to the lung or oesophagus which would result in overlap of fields if a T spine lesion will be treated)\n2. Patients with symptomatic spinal cord compression or cauda equina syndrome, resulting in bony compression or epidural compression of the spinal cord or cauda equine, respectively\n3. Patients with syndromes or conditions associated with increased radiosensitivity\n4. Patients with radiosensitive histologies, e.g. myeloma or lymphoma\n5. Contraindication to MRI, e.g. MRI-incompatible personal pacemaker in situ\n6. Patients with pre-existing osteoporotic fractures of the spine\n7. Prior treatment with any radionuclide within 30 days prior to registration\n8. Patients who have received chemotherapy within 1 week prior to administration of protocol RT or who are expected\u002Fplanned to receive chemotherapy during RT or within 1 week after completing protocol RT\n9. Uncontrolled intercurrent illness that is likely to interfere with treatment or assessment of outcomes, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements\n10. Evidence of any other significant clinical disorder or laboratory finding that makes it undesirable for the patient to participate in the study, or if it is felt by the research \u002F medical team that the patient may not be able to comply with the protocol and follow-up schedule due to psychological, familial, sociological or geographical conditions\n11. Significant or progressive neurological deficit such that emergency surgery or radiation required",{"count":149,"type":19},126,[104,22],"This study will look at treatment for patients that have already been diagnosed with cancer, but develop a new tumor(s) in the spine. Patients who are not recommended for surgery are usually treated with 5-10 sessions of radiotherapy to manage symptoms. For patients with a longer life expectancy (\\>6 months), it is better to give a higher dose of treatment to potentially improve the duration of pain relief, cancer control and potentially survival. Higher doses of radiotherapy, however, may also cause worse toxicity and side effects. This study will look at delivering higher doses of radiation in 2 sessions rather than 5-10, using a more modern, targeted technique called image-guided Stereotactic Ablative Body Radiotherapy (SABR). This method requires special equipment and expertise compared to the traditional radiotherapy and this has limited availability in Ireland. This study aims to find out the highest dose that is safe to be given to patients and carefully examine the side effects. These results will help create national and international guidelines to benefit all cancer patients. Patients will be monitored closely during treatment and for 2 years afterwards. Patients have been involved in developing the treatment protocol and the patient information leaflet. Patients will also be asked to fill in quality of life (QOL) questionnaires at certain timepoints during the study. It is anticipated that this study will support the delivery of high quality SABR to all cancer patients in Ireland, resulting in potentially better quality of life, symptom and tumor control.",[153],"Solid Tumor Spine Metastases",[153,155],"Dose-Escalated Stereotactic Ablative Body Radiotherapy","2025-04-29",{"date":158,"type":37},"2025-04-30",{"date":160,"type":37},"2023-11-21",{"date":162,"type":19},"2034-04-01",{"name":43,"class":44},{"id":165,"slug":166,"hasResults":11,"nctId":167,"briefTitle":168,"officialTitle":169,"acronym":170,"eligibilityCriteria":171,"healthyVolunteers":11,"sex":53,"minAge":16,"maxAge":4,"enrollmentInfo":172,"targetDuration":4,"studyType":20,"phases":174,"briefSummary":175,"conditions":176,"keywords":178,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":156,"lastUpdatePostDateStruct":185,"startDateStruct":187,"completionDateStruct":189,"leadSponsor":191,"locationsCount":116},"100391355","phase-2-source---lung-stereotactic-ablative-radiation-therapy-of-ultracentral-lung-tumours-source-lung-100391355","NCT04375904","'SOURCE - LUNG' Stereotactic Ablative Radiation Therapy Of UltRaCEntral LUNG Tumours (SOURCE Lung)","'SOURCE - LUNG' Stereotactic Ablative Radiation Therapy Of UltRaCEntral LUNG Tumours","SOURCE Lung","Inclusion Criteria:\n\n1. Written informed consent obtained prior to any study-specific procedures\n2. ≥ 18 years of age\n3. Life expectancy \\>6 months\n4. ECOG (Eastern Cooperative Oncology Group) performance status 0-2\n5. Histological diagnosis (biopsy or cytology) or radiological diagnosis (PET-positive FDG-avid tumour which has only one lesion to be treated for the purpose of the study \u002F CT-based diagnosis for non FDG-avid tumour) which requires local ablative therapy per Multi-Disciplinary Team (MDT) recommendations) of either:\n\n   (i) Primary NSCLC (Squamous Cell Carcinoma (SCC), Adenocarcinoma, Large Cell) OR (ii) Single pulmonary oligometastatic lesion to be treated for the purpose of the study\n6. Patients with central lung tumours\u002Flesions whose radiotherapy plan meets the following criteria:\n\n   (i) OAR eligibility constraints are initially exceeded when full PTV coverage is met; (ii) subsequently meets the CTRIAL-IE 18-33 SOURCE OAR Lung constraints and meets CTRIAL-IE 18-33 SOURCE Lung minimum constraints\n7. Inoperable (as per MDT) or patient refuses surgery,\n8. Females of childbearing potential must not be pregnant or lactating, must be prepared to take adequate contraception methods during treatment. Males whose female partners are of childbearing potential must be prepared to take adequate contraception methods during treatment. Examples of effective contraception methods are a condom or a diaphragm with spermicidal jelly, or oral, injectable or implanted birth control\n9. Absence of psychological, familial, sociological or geographical condition, or psychiatric illness\u002Fsocial situation potentially hampering compliance with the study protocol and follow-up schedule\n\nExclusion Criteria:\n\n1. Known co-existing or prior malignancy within the last 5 years (except for adequately treated basal cell carcinoma (BCC) or Squamous Cell Carcinoma (SCC) of the skin)) which is likely to interfere with treatment or assessment of outcomes\n2. Tumour\u002Foligometastatic lesion that is abutting the oesophagus\n3. Evidence of regional (nodal) or distant metastases or metastatic pleural effusion for patients with primary NSCLC\n4. Spinal canal involvement\n5. Patients with syndromes or conditions associated with increased radiosensitivity\n6. Idiopathic pulmonary fibrosis \u002F usual interstitial pneumonia\n7. Chemotherapy and\u002For other targeted therapy administered within 3 months prior to study radiotherapy or planned for \\\u003C6 weeks following radiotherapy for patients with primary NSCLC, or within 1 week prior to study radiotherapy or planned within 1 week following radiotherapy for patients with an oligometastatic lesion\n8. Any previous radiotherapy to the thorax or mediastinum (excluding previous breast or chest wall radiotherapy) which is likely to interfere with treatment or assessment of outcomes\n9. Any tumour not clinically definable on the treatment planning CT scan (e.g. surrounding consolidation or atelectasis)\n10. Patients unable to undergo 4D-CT scan\n11. Uncontrolled intercurrent illness that is likely to interfere with treatment or assessment of outcomes\n12. Evidence of any other significant clinical disorder or laboratory finding that makes it undesirable for the patient to participate in the study, or if it is felt by the research \u002F medical team that the patient may not be able to comply with the protocol.",{"count":173,"type":19},68,[22],"This is a phase II, non-randomised study examining the safety of treating high risk centrally located non-small cell lung cancer (NSCLC) tumours and single pulmonary oligometastatic lesions using radiation therapy (RT), for patients whose disease is inoperable. The method of delivering the RT in this study is image guided stereotactic ablative radiation therapy (IG-SABR). This method involves using imaging to ensure the radiation is being delivered to the correct location within the body and using higher than normal doses per treatment (fraction) to treat the lung cancer (NSCLC)\u002Foligometastatic lung lesion. This study aims to determine its safety by looking at the number and severity of side effects. This study will deliver 8 treatments\u002Ffractions of RT with 7.5 Gy delivered in each fraction. To be eligible for this study the initial treatment plan for the patient must be shown to not fulfil certain criteria relating to doses to the tumour and surrounding normal tissue. This study has its own study specific criteria which must be adhered to. Translational sub-studies (optional) are open to patients in participating centres only. Patients will have the option to consent to participating in both translational studies or to neither.",[177],"NSCLC\u002FOligometastatic Cancer (Single Lung Lesion)",[179,180,181,182,183,184],"Lung cancer","Non-small cell lung cancer","Ultracentral","Stereotactic ablative radiation therapy","Oligometastatic cancer","Single lung lesion",{"date":186,"type":37},"2025-05-02",{"date":188,"type":37},"2020-12-22",{"date":190,"type":19},"2032-02",{"name":43,"class":44},""]